Clinical trials: Blood Plasma Therapy
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00054158
- Testing
- dexamethasone, doxorubicin hydrochloride, thalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Acute Liver Failure
Plasma Exchange for Amanita Toxin-induced Acute Liver Failure
Retrospective evaluation of the value of additive therapeutic plasma exchange (PEX) compared to standard medical therapy (SMT) in Amanita toxin-associated acute liver failure in children and adolescents within the last 10 years…
- Trial name
- Amanita-Pex (NCT06187220)
- Testing
- Therapeutic Plasma Exchange (PEX)
- Where
- 6 sites in Germany, Italy and 3 more
- Volunteers
- 111 people
- Sponsor
- Hannover Medical School
Non-Hodgkins Lymphoma, B-cell Lymphoma
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
- Conditions
- Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma
- Trial name
- NCT01647971
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- TG Therapeutics, Inc.
Peyronie Disease, Sexual Dysfunction, Physiological
PRP for Treatment of Peyronie's Disease
The purpose of this study is to learn about the effects of Platelet-Rich Plasma (PRP) injection in men with Peyronie's Disease (PyD).
- Conditions
- Peyronie Disease, Sexual Dysfunction, Physiological, Sexual Dysfunction Male, Genital Diseases, Male
- Trial name
- NCT04512287
- Testing
- Autologous Platelet-Rich Plasma (PRP)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Miami
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
This phase II MATCH treatment trial identifies the effects of nivolumab in patients whose cancer has a genetic change called mismatch repair deficiency.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439214
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Onychomycosis Due to Trichophyton Rubrum, Onychomycosis Due to Trichophyton Mentagrophytes
Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)
Early feasibility study to determine if a three-treatment protocol with the RenewalNail™ plasma treatment system over a week will result in mycological cure and/or clear nail growth on the treated hallux toe.
- Trial name
- NCT03072550
- Testing
- RenewalNail™ Plasma Treatment System
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- DeviceFarm, Inc.
Multiple Myeloma
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate or thalidomide and Zometa is in controlling the myeloma disease and to study any side effects.
- Trial name
- NCT00083382
- Testing
- Pamidronate, Thalidomide, Zometa
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- University of Arkansas
Rectovaginal Fistula, Anovaginal Fistula
Feasibility and Safety of Additional Injection of Autologous Platelet-rich Stroma to Surgical Treatment of Rectovaginal Fistulas
Is the addition of platelet-rich stroma (PRS) injection, a form of autologous call therapy, to surgical treatment for rectovaginal fistula feasible and safe? The primary endpoints of this study are feasibility and safety until 12…
- Trial name
- PRS-RVF (NCT06798935)
- Testing
- autologous platelet-rich stroma
- Where
- Netherlands
- Volunteers
- 21 people
- Sponsor
- Erasmus Medical Center
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
This phase II trial studies how well romiplostim works in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy. Romiplostim may cause the body to make platelets after chemotherapy
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01676961
- Testing
- romiplostim
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NYU Langone Health
Waldenstrom Macroglobulinaemia, Multiple Myeloma
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases.
- Trial name
- BLOOD-dose (NCT07474961)
- Testing
- teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib)
- Where
- 5 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Anne Louise Tølbøll Sørensen
Antibody-mediated Rejection
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
This is a double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).
- Trial name
- NCT03221842
- Testing
- C1-esterase inhibitor
- Where
- 26 sites in United States, Belgium and 5 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring
Multiple Myeloma
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk…
- Trial name
- NCT03104842
- Testing
- Isatuximab, Carfilzomib, Lenalidomide
- Where
- 17 sites in Germany
- Volunteers
- 246 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Smoldering Plasma Cell Myeloma
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma.
- Trial name
- NCT05014646
- Testing
- Cholestyramine, Leflunomide
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
COVID19
Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection
This clinical trial proposal is based on the FDA protocol for emergency use of convalescent plasma for treatment of COVID-19 cases, and on the WHO guidelines for use of convalescent plasma in other infectious diseases.
- Trial name
- CP IN COVID19 (NCT04438694)
- Testing
- Convalescent Plasma, Standard of Care
- Where
- Egypt
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Cairo University
Amyloidosis; Systemic, AL Amyloidosis
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close to 60%.
- Trial name
- NCT06192979
- Testing
- Daratumumab, Bortezomib, Dexamethasone
- Where
- 7 sites in China
- Volunteers
- 41 people
- Sponsor
- Jin Lu, MD
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Personalized NK Cell Therapy in CBT
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT02727803
- Testing
- Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free…
- Trial name
- Cassiopeia (NCT02541383)
- Testing
- Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD), Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab, Daratumumab
- Where
- 107 sites in Belgium, France and 1 more
- Volunteers
- 1,085 people
- Sponsor
- Intergroupe Francophone du Myelome
Osteo Arthritis Knee, Knee Osteoarthritis
Knee Arthritis Treatment With Autologous Fragmented Adipose Tissue and PRP - Comparison of Two Treatment Methods
This is a prospective, randomized, controlled study. The purpose of this study is to assess functional and clinical changes among patients with symptomatic knee OA treated with intra-articular injections of autologous adipose…
- Conditions
- Osteo Arthritis Knee, Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- Trial name
- NCT04321629
- Testing
- autologous adipose tissue transfer, PRP injections
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Rehasport Clinic
Myeloma
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
The objective of this exploratory study is to evaluate, for the first time, the sensitivity of 18F-Fludarabine to the initial diagnosis of MM compared to FDG-PET and MRI.
- Trial name
- Myelofludate (NCT03832127)
- Testing
- 18F-Fludarabine
- Where
- 7 sites in France
- Volunteers
- 35 people
- Sponsor
- Nantes University Hospital
COVID-19
Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients
Given the current lack of an effective drug or therapy, a clinical trial to better understand the safety and efficacy of therapeutic plasma exchange (TPE) in COVID-19 patients is urgently needed.
- Trial name
- NCT04592705
- Testing
- Therapeutic plasma exchange
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Larkin Community Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.